Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 26,086 calls trading, 1.1x expected, and implied vol increasing almost 32 points to 119.88%. 10/31 weekly 6 calls and Oct-25 5.5 ...

Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

(MENAFN- GlobeNewsWire - Nasdaq) Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion ...

It is certainly possible that today’s bottlenecks will prove to be rather short-lived as companies increasingly learn to ...

Recursion Pharmaceuticals (RXRX) has grabbed attention following the announcement of its merger with Exscientia, as well as updates on late-stage trial milestones and new regulatory clearances for ...

The Dark Enlightenment of AI has turned efficiency into ideology. Here’s how it’s reshaping brands, leadership, and the ...

Over the past few years, API security has gone from a relatively niche concern to a headline issue. A slew of high-profile breaches and compliance mandates like PCI DSS 4.0 have woken security teams ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...